17 Results for "

hepatic cholesterol synthesis

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "hepatic cholesterol synthesis" in MCE Product Catalog:

9
9 Publications Verification
Cat. No.: HY-104081
CAS No.: 11041-12-6
Synonyms: Cholestyramine resin; Colestyramine
Cholestyramine (Cholestyramine resin) is an orally active bile acid sequestrant. Cholestyramine upregulates the expression of intestinal Apical sodium-dependent bile acid transporter and hepatic Cholesterol 7α-hydroxylase. Cholestyramine induces the expression of intestinal and hepatic cholesterol synthesis genes as well as hepatic lipogenesis genes, and promotes bile acid- and neutral sterol-mediated reverse cholesterol transport. Cholestyramine reduces intestinal cholesterol absorption and induces cholesterol efflux. Cholestyramine is applicable to research related to coronary artery disease, atherosclerotic cardiovascular disease and atherosclerosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0468
CAS No.: 63279-13-0
Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-116290
CAS No.: 142561-96-4
Purity:  99.2%
Synonyms: Squalestatin S1
Zaragozic acid A is a fungal metabolite that acts as a reversible competitive inhibitor of squalene synthase. Zaragozic acid A is an inhibitor of acute hepatic cholesterol synthesis in mouse (IC50 = 6 μM) .
loading...
    loading...
Cat. No.: HY-153491
CAS No.: 2097587-83-0
Synonyms: ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx
Target:  

Apolipoprotein

Research Areas:  

Cardiovascular Disease

Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) is a GalNAc-modified antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .
loading...
    loading...
Cat. No.: HY-153491A
CAS No.: 2298451-31-5
Purity:  91.44%
Synonyms: ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium
Target:  

Apolipoprotein

Research Areas:  

Cardiovascular Disease

Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) sodium is a GalNAc-modified antisense oligonucleotide. Olezarsen sodium binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen sodium reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen sodium is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .
loading...
    loading...
Cat. No.: HY-128828
CAS No.: 265989-46-6
Purity:  98.01%
2-Hydroxy atorvastatin calcium salt is an orally active OATP1B1 substrate and inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase). 2-Hydroxy atorvastatin calcium salt enters cells via OATP1B1-mediated cellular uptake and inhibits de novo hepatic cholesterol synthesis. As an active metabolite of Atorvastatin (HY-B0589), 2-Hydroxy atorvastatin calcium salt contributes to the inhibitory activity against plasma HMG-CoA reductase. 2-Hydroxy atorvastatin calcium salt can be biotransformed into an inactive lactone form, which can be hydrolyzed back to its active acid form chemically or enzymatically. 2-Hydroxy atorvastatin (calcium salt) can be used in the research of hypercholesterolemia .
loading...
    loading...
Cat. No.: HY-142026
CAS No.: 142449-89-6
Synonyms: (+)-Vitisin A
Vitisin A ((+)-Vitisin A) is an orally active natural product with multiple pharmacological activities including anti-inflammatory, anti-tumor, anti-oxidant, anti-pathogenic microorganism, hypoglycemic and lipid-regulating, anti-osteoporotic, neuroprotective and cardiovascular protective effects. Vitisin A exhibits inhibitory effects on human AChE and MAO-B with IC50 values of 1.29 µM and 4.94 µM, respectively. Vitisin A inhibits the ERK, MAPK, NF-κB, STAT1, HMGCR and TRAF6 pathways, downregulates the related phosphorylation and protein expression, while activates the Nrf2/HO-1 pathway and upregulates p21 expression. Vitisin A induces tumor cell apoptosis and cell cycle arrest, inhibits adipogenesis and lipid accumulation, while alleviates oxidative stress, suppresses inflammatory responses, blocks hepatic fibrosis, Cuproptosis and cholesterol synthesis, and increases the expression levels of central BDNF and TrkB. Vitisin A can be used in the research of tumors, infectious diseases, metabolic diseases, bone and joint diseases, liver diseases, skin injuries, as well as neurodegenerative and cognitive dysfunction-related diseases .
loading...
    loading...
Cat. No.: HY-11088
CAS No.: 887702-61-6
Research Areas:  

Metabolic Disease

PF-3052334 is an orally active, hepatically selective HMG-CoA reductase inhibitor with an IC50 of 1.9 nM. PF-3052334 inhibits cholesterol synthesis, with IC50 values ​​of 0.9 and 730 nM in hepatocytes and muscle cells, respectively. PF-3052334 can be used to study hypercholesterolemia .
loading...
    loading...
Cat. No.: HY-W015467
CAS No.: 636-73-7
Synonyms: Pyridine-3-sulphonic acid
Pyridine-3-sulfonic acid (Pyridine-3-sulphonic acid) is an orally active structural analog of Nicotine acid (HY-B0143). Pyridine-3-sulfonic acid significantly reduces hepatic cholesterol synthesis in rats but lacks cholesterol-lowering activity. Pyridine-3-sulfonic acid does not interfere with the metabolism of Nicotine acid .
loading...
    loading...
Cat. No.: HY-N0468R
CAS No.: 63279-13-0
Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
loading...
    loading...
Cat. No.: HY-119449
CAS No.: 519-95-9
Synonyms: Zanchol
Target:  

Others

Research Areas:  

Inflammation/Immunology

Florantyrone (Zanchol) is a bile-promoting agent. Florantyrone increases the volume of bile rather than the content of bile acids. Zanchol can stimulate the synthesis of cholesterol in the liver, significantly raising the plasma cholesterol level, increasing the weight of the liver, but has no significant effect on the synthesis of cholesterol in the intestine. Florantyrone can be used in research on biliary motility disorders .
loading...
    loading...
Cat. No.: HY-101812
CAS No.: 56488-59-6
Purity:  98.39%
Research Areas:  

Metabolic Disease

Terbufibrol is an orally active lipid-lowering agent. Terbufibrol inhibits hepatic Cholesterol 7 alpha-hydroxylase. Terbufibrol blocks a step between Acetate and HMG-CoA in the hepatic cholesterol synthesis process. Terbufibrol reduces serum total cholesterol, HDL, LDL, lipoprotein levels, and the cholesterol/phospholipid ratio, with dose- and sex-dependent changes in lipoprotein components. Terbufibrol exerts sustained cholesterol-lowering activity in baboons and rats. Terbufibrol can be used in research related to hypercholesterolemia .
loading...
    loading...
Cat. No.: HY-105281
CAS No.: 130200-44-1
Target:  

Drug Derivative

Research Areas:  

Metabolic Disease

rel-(E)-BMY 21950 sodium is the relative configuration of BMY 21950 (HY-105281A). BMY 21950 is an HMG-CoA reductase inhibitor. BMY 21950 inhibits hepatic cholesterol synthesis .
loading...
    loading...
Cat. No.: HY-101812R
CAS No.: 56488-59-6
Terbufibrol (Standard) is the analytical standard of Terbufibrol (HY-101812). This product is intended for research and analytical applications. Terbufibrol is an orally active lipid-lowering agent. Terbufibrol inhibits hepatic Cholesterol 7 alpha-hydroxylase. Terbufibrol blocks a step between Acetate and HMG-CoA in the hepatic cholesterol synthesis process. Terbufibrol reduces serum total cholesterol, HDL, LDL, lipoprotein levels, and the cholesterol/phospholipid ratio, with dose- and sex-dependent changes in lipoprotein components. Terbufibrol exerts sustained cholesterol-lowering activity in baboons and rats. Terbufibrol can be used in research related to hypercholesterolemia .
loading...
    loading...
Cat. No.: HY-E71772A
Research Areas:  

Others

3-Oxo-5-β-steroid 4-dehydrogenase from human (Recombinant) (EC 1.3.1.3) belongs to the NADPH-dependent short-chain dehydrogenase/reductase superfamily (AKR family). It catalyzes the 5β-reduction of the Δ4 double bond in steroid molecules and is involved in bile acid synthesis and steroid hormone metabolism, serving as a crucial enzyme for maintaining hepatic cholesterol metabolism and endocrine homeostasis.
loading...
    loading...
Cat. No.: HY-W563489
CAS No.: 88431-47-4
Synonyms: POCA
Clomoxir (POCA) is a carnitine palmitoyltransferase I (CPT I) inhibitor with hypoglycemic activity. Clomoxir mediates the inhibition of CPT I via its active form POCA-CoA. Clomoxir inhibits long-chain fatty acid oxidation, ketogenesis, gluconeogenesis, de novo synthesis of cholesterol and fatty acids, and also mildly inhibits acetyl-CoA carboxylase. Clomoxir reduces blood glucose levels in various rodent and porcine models, alters plasma NEFA and cholesterol concentrations, induces hepatic lipid accumulation, peroxisome proliferation and mild myocardial hypertrophy in rats, and stimulates the pentose phosphate pathway in cultured human fibroblasts. Clomoxir can be used in diabetes-related research .
loading...
    loading...
Cat. No.: HY-183483
CAS No.: 75987-18-7
Research Areas:  

Cardiovascular Disease

OKY-1581 is a potent, orally active and selective thromboxane A2 synthase inhibitor. OKY-1581 inhibits TXA2 synthesis and reduces the generation of its stable metabolite TXB2. OKY-1581 shifts arachidonic acid (MCE HY-109590) metabolism toward the production of prostaglandin E, prostaglandin F and 6-keto-prostaglandin F. OKY-1581 modulates the TXA2 / PGI2-related eicosanoid balance and inhibits arachidonic acid-induced platelet aggregation without directly inhibiting the cyclooxygenase step. At high oral doses, OKY-1581 also enhances hepatic peroxisomal β-oxidation and reduces serum triglyceride and cholesterol levels. OKY-1581 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage by reducing TXA2-related vasoconstrictive signaling. OKY-1581 can be used in studies of atherosclerosis, cerebral vasospasm after subarachnoid hemorrhage and cardiovascular diseases .
loading...
    loading...
  • 1